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Gaucher’s disease (GD) is caused by a β-glucocerebrosidase deficiency,
leading to the accumulation of glucocerebroside in the reticuloendothelial
system. The prevalence of GD in Tabuleiro do Norte (TN) (1:4000) is the
highest in Brazil. The purpose of this study was to present evidence of
consanguinity and founder effect for the G377S mutation (c.1246G>A)
among GD patients in TN based on enzyme, molecular and genealogical
studies. Between March 2009 and December 2010, 131 subjects at risk for
GD (GC in dried blood ≤2.19 nmol/h/ml) and 5 confirmed GD patients from
the same community were submitted for molecular analysis to characterize
the genetic profile of the population. Based on the enzymatic and molecular
analysis, the subjects were classified into three categories: affected (n= 5),
carrier (n= 20) and non-carrier (n= 111). All carriers were (G377S/wt).
Affected subjects were homozygous (G377S/G377S). The identification of a
single mutation in carriers and homozygotes from different generations, the
history of the community and the genealogy study suggest that the high
prevalence of GD in this population may be due to a combination of
consanguinity and founder effect for the G377S mutation.
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Founder effect is observed when a small subgroup of
a larger population establishes itself as a separate and
isolated entity (http://decs.bvsalud.org).
Gaucher’s Disease (GD) is caused by a deficiency of
the enzyme β-glucocerebrosidase (GCase, EC 3.2.1.45),
leading to the accumulation of glucocerebroside in
tissues, especially in the cells of the reticuloendothelial
system (1). Because the transmission of GD is autosomal
recessive, marital consanguinity favors the emergence
of phenotypic manifestations of recessive genes over
several generations.
Over 300 GD-related mutations have been described.
These may be classified into three types (null, severe
and mild) according to their phenotypic effect (2).
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The presence of mutations in both alleles may lead to
one of three phenotypical manifestations: type 1 non-
neuropathic (MIM 230800), type 2 neuropathic (MIM
230900) and type 3 subacute neuropathic (MIM231000).
The genotype/phenotype correlation is limited owing to
many variations in the clinical manifestations of patients
with the same genotype (3), although some genotypes are
associated with milder symptomatology.
The diagnosis may be established by the detection of
Gaucher cells in tissues, by GCase activity in leukocytes
or cultured skin fibroblasts, or by molecular analysis
(1, 4, 5). Populations at risk may be screened for GCase
and chitotriosidase activity using dried blood spots on
filter paper (DBS-FP) (6, 7).
GD is panethnic but is particularly prevalent among
Ashkenazi Jews. In the United States, the estimated
incidence is 1:40,000 (8). In Brazil, 566 GD patients had
been diagnosed by March 2014 (9).
In Tabuleiro do Norte (TN), a town in Northeastern
Brazil with approximately 28,500 inhabitants, the preva-
lence of GD is 1:4000 (10). The town was founded in the
second half of the 17th century by Portuguese settlers
of Sephardic Jewish extraction (11). A combination of
inbreeding, a common local practice until a few decades
ago, and founder effect for the G377S mutation, may
explain the high prevalence of GD in this population.
The objective of the study was to present evidence of
founder effect for the G377S mutation in a population of
GD patients and carriers from TN.
Methods
The molecular study protocol was approved by the
National Research Ethics Commission (CONEP) in
February 2009. The sampling was done in TN between 1
March 2009 and 31 December 2010.
The population study was based on three strategic pil-
lars: health education, screening for GD and genealogy
study of the families involved. Screening was done in
three steps (Fig. 1).
• Step 1: Evaluation of GCase and chitotriosidase activ-
ity in DBS-FP collected from residents of TN volun-
teering for the study (10).
• Step 2: Evaluation of GCase activity in leukocytes
and of chitotriosidase in plasma collected from par-
ticipants selected in Step 1 (10).
• Step 3: Molecular analysis of participants selected in
Step 2 and of five residents with confirmed GD.
The study started with population screening for GCase
activity for three reasons: (i) the genetic profile of the
population was unknown prior to the study, (ii) the cost
of large-scale DNA analysis was prohibitive and (iii)
genetic research facilities were unavailable in the region.
The participants were volunteers residing in TN
descended from local traditional families. All partici-
pants were required to attend at least one GD-related
health education session and to sign an informed con-
sent form. No financial or material compensation was
provided. Having been evaluated previously, relatives in
the first degree of patients with confirmed diagnosis of
GD were not invited to participate in the screening.
The evaluation of enzyme activity in DBS-FP was per-
formed with the technique developed by Civallero (7).
The cutoff values were≤2.19 nmol/h/ml for GCase activ-
ity in leukocytes and ≥44.00 nmol/h/ml for chitotriosi-
dase activity in plasma.
Participants below the GCase cutoff value or above
the chitotriosidase cutoff value in the first step of the
screening process were referred for evaluation of GCase
activity in leukocytes and chitotriosidase activity in
plasma according to standard methods described in
the literature (12, 13) and to DNA screening for four
common Brazilian mutations.
Screening for G377S, N370S, L444P and 55-del, the
most relevant mutations in Brazil (14), was performed
on exfoliated buccal mucosa cell DNA, as described in
the literature (15).
Patients found to be homozygous for G377S were
referred for screening for 55-del in the pseudogene
contiguous to theGBA gene (psGBA). When present, this
deletion occurs at the annealing sites of the primers used
for detecting N370S, L444P and G377S. If the presence
of 55-del is due to a recombination event, a false positive
result of homozygosis may occur.
To rule out the presence of mutations other than the
four mutations screened for, blood samples of partici-
pants with GCase activity in leukocytes ≤4.0 nmol/h/mg
protein were submitted for DNA sequencing of the gene
region encoding for GCase.
The statistical analysis was performed with the soft-
ware IBM SPSS version 20 (2011). The results were
expressed as distribution of frequencies, central ten-
dency, dispersion, minimum values and maximum
values. Categories were compared pairwise with
the Steel–Dwass–Critchlow–Fligner test for non-
parametric data. The Kruskal–Wallis test was used to
compare three categories simultaneously. The level of
statistical significance was set at 5% (p< 0.05).
The reconstruction of the genealogy of the involved
families was based on interviews with the participants,
their relatives and information provided by Prof Mar-
condes Andrade, a local historian. Using the software
GenoPro® 2011 version 2.5.4.1, genograms were built
from the collected data.
Results
During Step 1 of the population screening, 740 DBS-FP
samples were evaluated for GCase and chitotriosidase
activity. The participants were aged 31.4± 19.2 years
(range: 2–81) and most were women (n= 496; 67%). As
participation in this study was voluntary, we found that
women were more prone to collaborate. Nearly one fifth
(n= 135; 18.2%) were found to be at risk for GD (GCase
in DBS-FP ≤2.19 nmol/h/ml) (10).
In Step 2, four of the 135 participants at risk declined
participation. Thus, 131 participants (86 women) aged
34.17± 19.62 years (range: 2–77) were submitted for
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At risk
GCase ≤ 2.19  nmol/h/mL
Chito ≥ 44.00 nmol/h/mL
Normal
GCase > 2.19 nmol/h/mL
Chito < 44.00 nmol/h/mL
At risk
GCase 5.6 -16.4
nmol/h/mg
protein
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GCase >16.4 
nmol/h/mg
protein
At high risk
GCase ≤ 5.5 
nmol/h/mg
protein
Non-carrier Carrier Affected
Genetic counseling
Step1 Evaluation of glucocerebrosidase and chitotriosidase 
activity in dried blood on filter paper
Step 2 Evaluation of glucocerebrosidase activity in 
leukocytes and chitotriosidase activity in plasma
Step 3
Molecular analysis of mutations  
N370S, G377S, L444P and 55-del
DNA sequencing
Clinical evaluation
Lab tests
Ultrasonography
Bone densitometry
Radiology
Magnetic resonance
Fig. 1. Design of population screening for Gaucher’s disease in Tabuleiro do Norte, Ceará, Brazil, 2009–2010. Source: the authors.
evaluation of GCase activity in leukocytes, chitotriosi-
dase activity in plasma and screening for the mutations
N370S, L444P, G377S and 55-del (10).
A group of five patients with confirmed diagnosis of
GD and both parents descended from early settlers of
TN was added to the group of 131 participants selected
for screening for the mutations N370S, L444P, G377S
and 55-del in order to compare their genotypes to the
mutations identified in the 131 selected participants in
Step 1. The five patients were diagnosed between 1977
and 2007 based on GCase levels in leukocytes and
clinical symptoms only.
Screening for the four most common mutations in
Brazil resulted in the identification of G377S only,
making it possible to classify the participants in three
categories according to genotype: non-carriers (n= 111;
81.6%), carriers (n= 20; 14.7%) and affected (n= 5;
3.7%) (Table 1).
The DNA sequencing based on DBS-FP of the four
participants with GCase in leukocytes ≤4.0 nmol/h/mg
protein confirmed the diagnosis of two carrier subjects
(G377S/wt) and two non-carriers (wt/wt) (10).
Our genealogy study included 12 family generations
and 583 subjects (52.6% women) from 181 nuclear
families in TN who established 778 pedigree links
during a period of over 300 years. The earliest ancestor
identified by name was born in Cartaxo, Portugal, in
1646 (Family 1) and migrated to Brazil in 1690 along
with four children. Two of these settled in what was to
become TN and married the two daughters of a couple of
Portuguese descendants (Family 2). Inbreeding became
commonplace over time in the isolated rural community
of TN, favoring the emergence of homozygotes and
carriers of the mutation G377S (Fig. 2).
Our data provide evidence of significant levels of
inbreeding. Thus, although 66 different surnames were
registered among the 136 individuals in the final sample,
50% belong to only 8 families. The 20 carriers have 21
different surnames, but 47% have at least one surname in
common. Forty percent of the carriers reported that their
parents were cousins in the first degree.
The five affected subjects belong to four families
descended from common ancestors. Two are sisters, and
all are cousins of the second or third degree, suggesting
a strong pattern of consanguinity.
Discussion
The G377S mutation is the fourth most prevalent
GD-related mutation in Spain (n= 25; 3.0%) (2) and
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Table 1. Affected subjects, carriers and non-carriers of mutations for Gaucher’s disease according to gender, age and enzyme activity
(GCase activity in leukocytes and chitotriosidase activity in plasma)a
Subjects according to genetic status
Variables Non-carrier Carrier G377S/wt Affected G377S/G377S Total p-value
n (%) 111 (81.6) 20 (14.7) 5 (3.7) 136 (100)
Gender
Female n (%) 69 (62.2) 14 (70.0) 3 (60.0) 86 (63)
Male n (%) 42 (37.8) 6 (30.0) 2 (40.0) 50 (37) 0.791
Age (years)
Average 35.51 26.70 33.40 34.14
Standard deviation 20.20 14.25 10.35 19.34
Minimum–maximum 2–76 6–48 22–45 2–76
Conﬁdence interval (95%) 31.71–39.31 20.03–33.37 20.54–46.26 30.86–37.42 0.242
GCase (nmol/h/mg protein)
Average 10.47 6.70 1.92 9.48
Standard deviation 3.01 2.03 1.78 3.48
Minimum–maximum 4.00–20.00 2.60–10.00 0.13–4.80 0.13–20.00
Conﬁdence interval (95%) 9.90–11.40 5.74–7.65 0.00–4.14 9.01–10.20 <0.001
Chitotriosidase (nmol/h/ml)
Average 51.46 51.54 18,129.40 716.10
Standard deviation 57.42 32.64 8714.61 3729.00
Minimum–maximum 0.80–381.00 0.80–144.00 9110–31,543 0.8–31,543
Conﬁdence interval (95%) 40.66–62.26 36.26–66.81 7308–28,950 83.56–1349 <0.001
Type of mutation wt/wt G377S/wt G377S/ G377S - -
GCase, β-glucocerebrosidase.
aComparisons involving three categories simultaneously were done with the Kruskal–Wallis test. Pairwise comparisons of categories
were done with the Dwass–Steel–Critchlow–Fligner test for non-parametric data.
Source: The authors, 2010.
the third most prevalent in both Portugal (n= 4; 7.4%)
(16) and Brazil (n= 11; 2.2%) (14). Initially, it was
believed to be neuroprotective owing to its mild effect,
high residual enzyme activity and the fact that all known
Portuguese homozygotes for G377S have type 1 GD
(17). However, the G377S mutation has been observed
in patients with type 3 GD in both Brazil and the Iberian
Peninsula (2, 14).
Although cardiac valvulopathies have been observed
in a homozygous patient from Croatia, all our subjects
had type 1 GD and no cardiovascular symptoms. This
suggests that individuals with the same genotype may
have different phenotypes and highlights the influence of
other genetic and/or environmental factors on the clinical
manifestations of GD (2, 18).
The fact that the carriers and affected subjects identi-
fied in this study are descendents of Jewish immigrants
from Cartaxo, Portugal (11), and that the mutation
G377S has been observed in homozygosis in one Por-
tuguese Sephardic Jewish patient suggests that the
G377S mutation may be Sephardic in origin (16),
although the gene frequency of this mutation is not
significant among Jewish subjects (3, 19).
Genotype/biochemical phenotype correlations
The participants were classified into three genotype
categories: affected, carriers and non-carriers. The
categories did not differ significantly with regard to
average age (p= 0.242) or gender (p= 0.791) (Table 1).
In our sample, carriers and affected subjects dis-
played 56.72% (p< 0.001) and 18.3%, respectively, of
the average GCase activity in leukocytes of non-carriers.
However, despite the significant differences in average
GCase activity in leukocytes between the three categories
(p< 0.001), the enzyme tests were unable to distinguish
carriers reliably from non-carriers.
Chitotriosidase activity in plasma is usually above nor-
mal in GD. This makes the chitotriosidase test a use-
ful tool in the diagnosis and follow-up of GD patients
(12). In this study, average chitotriosidase activity levels
were significantly higher in affected subjects than in car-
riers (p= 0.002) and approximately 350 times higher in
affected subjects than in non-carriers (p< 0.001). How-
ever, carriers and non-carriers did not differ significantly
(p= 0.34).
We believe that the observed founder effect for the
G377S mutation may be attributed to the Portuguese
ancestors of the early settlers of TN. However, it remains
to be determined whether the presence of G377S in this
population is related to the Sephardic Jewish origin of
these ancestors.
In conclusion, the identification of a single mutation
(G377S) in 20 carriers and five affected subjects, belong-
ing to different generations but descending from com-
mon ancestors, suggests that the high prevalence of GD
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Fig. 2. Genogram of homozygotes and carriers of the mutation G377S in Tabuleiro do Norte. Source: the authors.
in TN is due to a combination of founder effect for the
G377S mutation and consanguinity.
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